Q2 2026 Biogen Inc Earnings Call Transcript
Key Points
- Biogen Inc (BIIB) reported strong revenue growth in the second quarter, with total pharmaceutical revenue reaching $1.8 billion, up 4% year over year.
- The company's growth portfolio, including SPINRAZA, LEQEMBI, and SKYCLARYS, generated over $1 billion in revenue, showing a 24% increase year over year.
- The acquisition of Apellis has strengthened Biogen Inc (BIIB)'s portfolio with SYFOVRE and EMPAVELI, contributing significantly to revenue growth.
- Biogen Inc (BIIB) has a robust late-stage pipeline with five registrational Phase 3 clinical trials expected to deliver results in the next four quarters.
- The company is actively rebuilding its early-stage pipeline, with three INDs filed this year and more expected, indicating a strong focus on long-term growth.
- Despite the strong performance, Biogen Inc (BIIB) faces challenges in the competitive market for SPINRAZA, with some patients switching back from oral therapies.
- The company anticipates a $0.85 non-GAAP EPS dilution in 2026 due to financing costs associated with the Apellis acquisition.
- Biogen Inc (BIIB) is experiencing increased operating expenses, with a 20% year-over-year rise in non-GAAP core OpEx, reflecting integration costs and pipeline investments.
- The market for LEQEMBI faces access challenges, with Part D coverage and prior authorization requirements potentially impacting patient uptake.
- Biogen Inc (BIIB) acknowledges the high-risk nature of its investment in Diranersen for Alzheimer's, which may not contribute to growth until the next decade.
Good morning. My name is Jess and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen second-quarter 2026 earnings call and business update. (Operator Instructions)Today's conference is being recorded.
Thank you. I would now like to turn the conference over to Mr. Tim Power, Head of Investor Relations. Mr. Power, you may begin your conference.
Thanks, Jess, and good morning, everyone. Welcome to Biogen's second-quarter 2026 earnings call. During this call, we'll make forward-looking statements, which involve risks and uncertainties that may cause actual results to differ materially from our forward-looking statements. We provide a comprehensive list of risk factors in our SEC filings, which I encourage you to review.
Our earnings release and other documents related to our results, as well as reconciliations between GAAP and non-GAAP results discussed on this call can be found in the Investors section of biogen.com. We've also posted slides to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
